| Working Group Events |
|---|
PHUSE Open Source Technology in Clinical Data Analysis are running a series of Open Forums this year. The forums have been open to the public since April and will continue most months until October. Each forum explores different topics and investigates questions. The next forum will look at Regulatory Acceptance of Open-Source Submissions.
So far this year we have had 12 virtual Working Group events, with more planned in the coming months. Over 1,500 attendees have attended our Working Group events so far this year! There are four events coming up within the Working Groups over the next few months: The Open Source Technology in Clinical Data Analysis (OSTCDA) project was set up with the aim to create a manuscript on the integration of open-source software solutions for clinical data management, analysis and reporting. Questions we will address during this Webinar:
In addition to the GitHub Discussion, we are hosting a series of forums throughout the year. See the Working Group Events page for further details. This Forum will be taking place over Zoom on 13 September at 15:00-16:00 (BST) / 10:00-11:00 (EDT). The PHUSE Data Transparency Autumn Event is taking place 17–19 September 2024. Data Transparency Events offer you the chance to gain knowledge and experience from a wide data transparency community, allowing you to come together with experts from a variety of companies and backgrounds. During this virtual event, presentations will be delivered across the three days in bitesize chunks from 15:00 to 17:30 (BST). There will also be a panel discussion and Q&A session focused on the days’ themes. Digital healthcare technologies (DHTs) show significant potential for enhancing data acquisition in clinical trials by enabling objective and accurate data collection. DHTs include wearable devices – sensors, smartwatches, fitness trackers – that continuously monitor vital signs, physical activity, sleep patterns, and medication adherence. Some DHTs, such as smartwatches, can be used in clinics and at home for remote patient monitoring. Moreover, DHTs facilitate real-time data monitoring and safety analysis, enabling prompt identification of trends, outliers and adverse events. This timely information supports early intervention and decision-making, thereby improving participant safety and overall trial efficiency. However, the emergence of DHTs also raises regulatory-related questions. In this PHUSE quarterly forum, we will discuss the development of digitally derived measures (clinical outcome assessments and biomarkers) and germane regulatory policies from the perspectives of government and industry experts. A significant amount of time and energy has been invested in recent years in exploring the desirability (do we want it?), feasibility (can we do it?) and viability (is it worth it?) of integrating open-source solutions into our clinical data pipelines, which transform source data into clinical study reports and submission data packages. In this October edition of the Open-Source Open Forum, we will update on the status of this initiative and continue to hear from you on what we’ve missed so far. When this manuscript is complete, we hope to put to rest some of the burning questions we believe we now know the answers to. This will allow industry, and all the passionate people in it, to look ahead and start tackling the next horizon of challenges related to using open-source solutions for clinical data pipelines. We hope you will contribute your expertise to this effort. |
| Community Forums |
|---|
TheUnderstanding the Complete Journey of RWD, From Data Source to Final Analysis project held its 3rd Community Forum in July, with 91 in attendance.In this forum, the speakers shared examples from their experiences of the step-by-step process of real-world evidence (RWE) generation, beginning with identifying appropriate RWD, mapping and cleaning the data to create the necessary analytic files, through to the final analysis resulting in RWE. They also highlighted the challenges they have faced and the solutions they have implemented. Examples covered include therapeutic areas such as adult growth hormone deficiency (AGHD), drug-resistant epilepsy, and Alzheimer’s disease. Through these examples, we hope it provided insights into the complexity of working with RWD and shared successful ways to overcome these challenges. |
| Open Source |
|---|
The Open Source Technology in Clinical Data Analysis (OSTCDA) project held its 4th Open Forum in June. There were 119 people in attendance, and the questions addressed were:
TheOpen Source Technology in Clinical Data Analysis (OSTCDA)held its 5th Open Forum, with 137 in attendance. Questions we addressed during this webinar:
|